Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Sustained hematologic complete response after discontinuation of ropeginterferon alfa-2b in patients with polycythemia vera].

[Rinsho ketsueki] The Japanese journal of clinical hematology - 1 Jan 2026

Maruta Masaki, Mori Kento, Oka Koji, Masuda Yuya, Kato Junichi, Konishi Tatsuya, Nabe Shogo, Miyazaki Yukihiro, Ochi Toshiki, Yamanouchi Jun, Takenaka Katsuto

Abstract excerpt

We report two cases of polycythemia vera (PV) treated with ropeginterferon alfa-2b (ropeg-IFN) in which hematologic control was maintained without therapy after treatment discontinuation. The patients achieved complete response (CR) at 14 and 22 weeks after treatment initiation, respectively. After discontinuation of ropeg-IFN, Patient 1 has maintained hematocrit (Ht) <45% for 3 years and 3 months, while patient...

Topics

Join the communities discussing this publication.

Alleles
Interferon-alpha
Interferon alpha-2
Janus Kinase 2
Polycythemia Vera

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Polyethylene Glycols

Recombinant Proteins

Treatment Outcome

Source

Identifiers

PMID: 41905908
DOI: 10.11406/rinketsu.67.205

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Sustained hematologic complete response after discontinuation of ropeginterferon alfa-2b in patients with polycythemia vera].PMID 41905908Read ↗

Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera.Semantic proximity Read ↗

Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study.Semantic proximity Read ↗

Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.Semantic proximity Read ↗

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.Semantic proximity Read ↗

A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.Semantic proximity Read ↗

Real-life use of ropeg-interferon α2b in Polycythemia Vera: patient selection and clinical outcomesSemantic proximity Read ↗

Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.Semantic proximity Read ↗

Real-world experience with Ropeginterferon-alpha 2b (Besremi) in Philadelphia-negative myeloproliferative neoplasms.Semantic proximity Read ↗

[Interferon-alpha-2b induces molecular responses of patients with polycythemia vera and its post-polycythemic myelofibrosis].Semantic proximity Read ↗

Complete molecular remission in a polycythaemia vera patient 12 years after discontinuation of interferon-alpha.Semantic proximity Read ↗

Mechanism of Action of Ropeginterferon Alfa-2b in Polycythemia Vera TreatmentSemantic proximity Read ↗

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.